INTRODUCTION
Using genetics to characterize response to pharmacological treatments offers a new approach to tailoring antihypertensive treatment to a given patient. The goal of pharmacogenetic studies is to enhance the understanding of the genetic nature of drug response based on the interaction of individual genetic architecture and antihypertensive therapy. Hypertension susceptibility genes may interact with the type of antihypertensive medication to modify blood pressure response to treatment and/or risk of coronary heart disease. There is large inter-individual variability in response in efficacy and tolerability to various classes of antihypertensive agents, and often hypertensive patients are refractory to particular drugs. Targeting treatment to the genetic component of pathogenesis may enhance treatment efficacy and improve overall benefit, resulting in more effective blood pressure control, lower incidence of hypertensionrelated morbidity and mortality, and better use of limited economic resources. 1, 2 New treatment modalities in the 1970s generated much excitement about devising treatment strategies targeted to hypertensive mechanisms. However, physiologic and epidemiologic profiling of patients to assist in antihypertensive selection did not achieve its potential. With the recent advances in the ability to rapidly genotype large numbers of genetic variants, pharmacogenetic studies that examine the influence of genetic variation in the response to medications are now possible. 3 Hypertension is a complex disorder, influenced by multiple genes and environmental mediators of risk, and the pharmacogenetic basis of antihypertensive drug response is likely to also be complex. Table 1 describes several physiological systems contributing to blood pressure variation, the genetic polymorphisms identified within these systems, including polymorphisms tested by GenHAT, and phenotypic correlates for which gene-treatment interactions may have relevance.
There is a paucity of information regarding interactions of genetic variants with antihypertensive treatments and the modification of blood pressure response or cardiovascular outcomes. A few studies suggest specific polymorphisms in hypertension candidate genes predispose individuals to differential response to blood pressure lowering medication. For example, adducin, which plays a functional role in modulating cellular sodium transport, affects response to diuretics. Among 58 previously untreated hypertensives treated with 25 mg hydrochlorothiazide for 2 months, the a-adducin Gly-Trp variant was genotyped. 4 Patients with the Gly/Trp genotype were significantly (nearly 5-fold) more responsive to the diuretic compared to Gly homozygotes. Most other published reports examined the relation between the angiotensin converting enzyme (ACE) insertiondeletion (ID) polymorphism and treatment with a variety of antihypertensive agents on cardiovascular and renal outcomes (see Table 2 ). Four of these studies suggested that ACE I/D 'DD' genotype was more responsive to antihypertensive treatment, while two suggested the 'II' genotype was. However, most studies were small (ie, fewer than 100 patients), were observational (ie, subjects were not randomized to a treatment) and were restricted to surrogate markers of cardiovascular risk (ie, blood pressure, left ventricular mass, or proteinuria).
The goal of GenHAT (Genetics of Hypertension Associated Treatment) is to determine whether variants in several hypertensive genes interact with the type of antihypertensive drug to modify the risk of CHD and other cardiovascular endpoints. To our knowledge, GenHAT is the largest pharmacogenetic study ever conducted. GenHAT is genotyping six candidate genes from loci involved in blood pressure regulation, such as the renin-angiotensinaldosterone system, sodium-volume homeostasis, and insulin resistance, and plans to type 10 additional genes as evidence emerges regarding their importance in blood pressure regulation. For some variants, current studies support drug-gene interactions with surrogate markers of CHD (eg, a-adducin and AGT). For other genes lacking such empirical evidence, GenHAT developed hypotheses based on knowledge of the drug's action and pathways for CHD development (eg, b2 adrenergic receptor and LPL).
METHODS

Overview
In addition to the large sample size and the ethnic and gender diversity of the sample, a major strength of GenHAT is the ability to link gene-treatment interactions with important clinical outcomes. GenHAT's primary hypothesis is that the association between the type of antihypertensive Table 3 . Secondary objectives of the GenHAT study are fourforld. We will: (1) examine the primary questions with different comparator groups, eg for the AGT-6 hypothesis instead of lisinoprilassigned participants vs all others, we will examine lisinopril assigned individuals vs chlorthalidone-assigned, amlodipine-assigned, or doxazosin-assigned ones; (2) examine the six primary questions using the other declared outcomes of the ALLHAT trial, including: (a) all-cause mortality; (b) combined coronary heart disease (CHD + revascularization procedures + hospitalized angina); (c) fatal and non-fatal stroke; (d) combined cardiovascular disease; (e) congestive heart failure; (f) peripheral arterial disease; (g) left ventricular hypertrophy; (h) decreased renal function; (i) endstage renal disease; and (j) blood pressure lowering; (3) assess all of the above questions in key pre-specified subgroups (over age 65, women, African-Americans, type 2 diabetics); and (4) apply items (1)-(3) to the 10 additional candidate genes to be typed in the future. All analyses will be conducted first in the entire sample. Possible race and sex interactions with genes and treatments will also be examined.
GenHAT is an ancillary study of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 5 ALLHAT is sponsored by the National Heart, Lung and Blood Institute and Department of Veterans' Affairs. ALLHAT is a randomized, double-blind, multi-center clinical trial of 42 411 participants that is designed to determine if the incidence of fatal CHD and nonfatal myocardial infarction (MI) in high-risk hypertensive patients is lower with treatment with each of three newer antihypertensive drug classes: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alphaadrenergic blocker (doxazosin) compared to treatment with a diuretic (chlorthalidone). 5 Secondary endpoints include all-cause mortality, stroke and other cardiovascular events. A lipid-lowering trial involving a subset of participants is designed to determine if lowering cholesterol with an HMG Co-A reductase inhibitor (pravastatin) compared to usual care reduces all-cause mortality in older moderately , the doxazosin arm was discontinued because of futility for the primary endpoint (part of the a priori stopping guidelines for ALLHAT), 5 and a significantly increased occurrence of the secondary endpoint, major cardiovascular disease (CVD), (RR ¼ 1.25 95% CI 1.17-1.33, P o 0. 001), especially congestive heart failure (CHF) (RR ¼ 2.04; 95% CI 1.79-2.32, P o 0.001), in the doxazosin arm compared with the chlorthalidone arm. Regarding futility, there was a very low probability that doxazosin would show benefit over chlorthalidone for the primary endpoint (fatal CHD or nonfatal MI) by the scheduled end of the study, given the lack of difference (RR ¼ 1.02, 95% CI 0.90-1.17, P ¼ 0.71) at that point in follow-up.
ALLHAT recruitment, randomization, treatment and clinical visits ALLHAT is a practice-based, active-control, randomized clinical trial with 42 411 high-risk hypertensives ages 55 years and older recruited in 623 clinical centers. ALLHAT recruited African-Americans, Hispanic whites and Hispanic blacks in larger proportions than that of the US population, the last two groups primarily through clinical centers in Puerto Rico, Texas and California, to enhance the study's ability to evaluate the benefit of various treatments in relation to CHD in minorities. Details of the study design are published elsewhere. 6 Blood pressure eligibility for ALLHAT was based on current antihypertensive medication use and/ or the average of 2-seated BP measurements during the two pre-randomization visits. For untreated patients, or patients taking blood pressure lowering drugs for less than 2 months, systolic or diastolic blood pressure levels fell between 140 and 180 mmHg and 90 and 110 mmHg, respectively, at each of two consecutive visits. For participants currently taking blood pressure lowering drugs for 4 2 months, systolic or diastolic blood could not exceed 160/100 mmHg at the first visit, or 180/110 mmHg at the second visit, the latter criterion reflecting the anticipated increase in blood pressure following discontinuation of antihypertensive therapy. Detailed inclusion and exclusion criteria are published 6 (see Table 4 ). In addition, eligible subjects had at least one additional CV risk factor, including previous myocardial infarction or stroke, type 2 diabetes, current cigarette smoking, left ventricular hypertrophy by electrocardiogram or echocardiography, or low high-density lipoprotein cholesterol level. Because of the inclusion of the additional risk factor, a large proportion of the sample is diabetic. Informed consent was obtained for each patient and the protocol approved by each participating center's Institutional Review Board.
Participants were randomized to one of four ALLHAT treatment arms, chlorthalidone, lisinopril, amlodipine, and doxazosin, in a ratio of 1.7:1:1:1, respectively. Randomization was stratified by clinical center. The treatment was In individuals with the H1H1; H1H2 genotypes, the relative risk of CHD in doxazosin-assigned participants vs all others will be lower than the relative risk for doxazosin-assigned participants vs all others in those with the H2H2 genotype given once daily: chlorthalidone (12.5 mg for the first and second titration and 25 mg for the third), lisinopril (10, 20 or 40 mg), amlodipine (2.5, 5 or 10 mg), or doxazosin (2, 4 or 8 mg). All study medications were identical in appearance to assure masking at each dosage level. The treatment goal was to achieve blood pressure control (systolic blood pressure less than 140 mmHg and diastolic blood pressure less than 90 mmHg). The therapeutic objective was to achieve goal blood pressure on the lowest possible dosage of the first-line drug. All participants were started on the lowest available dose and titrated to achieve blood pressure control. If blood pressure control was not achieved on the maximum study medication dose, a secondline open-label agent (reserpine, clonidine or atenolol) and/ or a third-line open-label agent (hydralazine) was added. Information about compliance to study medication was collected at each clinic visit. At 6 months about 71% were on one drug, about 26% were on two or more drugs and about 3% were on no drugs.
Once the goal blood pressure was met, and the medication regimen stable, routine clinic visits were scheduled at 3-month intervals during the first year and 4-month intervals thereafter. Blood pressure was measured in duplicate, preferably with a standard mercury sphygmomanometer, in participants who were seated quietly, with feet flat on the floor, in an erect but comfortable posture for at least 5 min. Study coordinators attended a centralized blood pressure training, and subsequently trained other clinical center staff. Periodic retraining/recertification is done by study coordinators on site. Height and weight were measured. ECGs were collected at baseline and years 2, 4 and 6 of follow-up and read centrally using the Minnesota Code. Laboratory measurements were collected following an 8-h fast at baseline and years 1, 2, 4 and 6 after randomization. The analytes included potassium, glucose, creatinine, total cholesterol, HDL cholesterol, triglycerides, and alanine aminotransferase.
ALLHAT outcomes
The primary outcome for ALLHAT's hypertension trial, and GenHAT, is the combination of CHD death and non-fatal MI. There are a priori secondary outcomes to be examined by ALLHAT and GenHAT. These include all-cause mortality, combined CHD outcomes (CHD plus revascularization procedures plus hospitalized angina), fatal and non-fatal stroke and combined CV disease (CHD death, non-fatal MI, stroke, revascularization procedure, angina (in-hospital or treated as an out-patient), congestive heart failure (inhospital or treated as an out-patient), or peripheral arterial disease (in-hospital an out-patient revascularization)). Additional outcomes of interest include left ventricular hypertrophy by ECG, decreased renal function and end-stage renal disease (see Davis et al 1996 for further details).
ALLHAT investigators query patients about outcomes at each follow-up visit and the information is submitted to the coordinating center (CTC). End-points are reported by the clinical investigator. However, death certificates and hospitalization records are used to support the clinician-assigned outcomes, and the documentation is verified by the CTC. ALLHAT conducts periodic searches through national databases (VA, National Death Index and the Health Care Finance Administration) to ascertain deaths and hospitalization end-points that might be missed by the clinical sites.For quality control purposes, more detailed information is collected on a randomly-selected 10% sample of fatal CHD and stroke, and hospitalized MI and stroke to validate the outcome with documentation of procedures and results. These are reviewed by an End-points Committee to determine whether events met a priori defined study criteria. For fatal CHD and non-fatal MI, the agreement rate between the clinician-assigned outcome and that of the End-points Committee exceeds 90% (ALLHAT Collaborative Research Group, 2000).
GenHAT investigators are also evaluating change in blood pressure with treatment at 6 months. Six months was 
Genotyping methods
GenHAT is using a simple, fast and inexpensive method, FTA t paper, to isolate DNA. The FTA s paper (Fitzco Inc, Maple Plain, MN, USA), is designed to completely immobilize DNA within the cellulose fiber paper matrix. When blood samples are applied to the paper, membranes are disrupted and high molecular weight DNA becomes entangled in the paper fibers. The DNA from the sample remains immobilized on the collection paper while proteins and other contaminants are selectively removed by washing. A 1.5 mm disk is punched out and washed with FTA PCR amplification is done in 96-well plates using robotic workstations and multichannel pipettes. Amplifications are carried out in a final volume of 20 ml containing standard concentrations of primer, dNTPs, buffer and 0.5 units of Taq polymerase. Each amplification series contains a negative control (water) to ensure absence of contamination of the amplification reaction and a sample of known genotype. Because of the requirement for genotyping large numbers of hypertensives, GenHAT is using Taqman technologies for rapid and efficient typing of each polymorphic system, with the exception of ACE I/D variant. For high throughput genotyping of a fixed set of SNPs on a large number of individuals, short PCR product (60-100 bases) with a linker and modifier end are covalently bound to a coated glass slide. The bound PCR product is washed with labeled allelespecific probes to detect the presence of each allele according to established methods. 4, [7] [8] [9] [10] [11] [12] High throughput genotyping data generation requires careful data management. Lane tracking and band calling and sizing are performed on networked computers. Genotype testing includes in each batch known control samples that are normal, heterozygous and homozygous for the variant being tested. A 'no template' reaction is used in each batch to monitor potential contamination. In addition, blind duplicates are included in each tray to assess reproducibility. Tests for Hardy-Weinberg equilibrium are carried out weekly at each genotyping laboratory.
Anonymization of DNA samples GenHAT adopted guidelines set forth in the 'Report of the Special Emphasis Panel on Opportunities and Obstacles to Genetic Research in NHLBI Clinical Studies', published at 'http://www.nhlbi.nih.gov/meetings/workshop/opporsep.txt'. The report classifies studies by the temporal status: completed, ongoing and future studies. ALLHAT falls into the 'ongoing' class of studies. The Report, in its section on 'Protecting Human Subjects', adopted definitions used by the American Society of Human Genetics. 13 It classifies existing specimens as: (1) anonymous specimens originally collected without identifiers and impossible to link to their sources; (2) anonymized specimens initially identified, but irreversibly stripped of all identifiers and impossible to link to their source; (3) identifiable specimens unidentifiable for research purposes, but can be linked to their sources through the use of a code; and (4) identified specimens for which identifiers are attached and made available to researchers. The GenHAT specimens fall into category three at present, but once ALLHAT data collection is complete and the nonidentifiying data transferred to the GenHAT database via the 'key file' linking ALLHAT IDs to GenHAT IDs, we will destroy the key file. The GenHAT data will then move into anonymization category two.
Operationally, GenHAT DNA samples are anonymized at the time of the DNA isolation. To simplify the anonymization plan, a new identification number is assigned with a numbering system based on the tray, row and column number for each participant's DNA sample. Study data are tracked and stored using the GenHAT ID. The key linking the ALLHAT ID with the new GenHAT number is sent to the ALLHAT Clinical Trials Center as samples are transferred from the Central Laboratory, and all records of the key destroyed at the Central Laboratory once the CTC confirms its arrival. The key is kept in an offline, locked file at the coordinating center.
Hypotheses and study power
The six primary study hypotheses are listed in Table 3 . One example of a primary question is whether the relative risk of combined fatal CHD and nonfatal MI for those hypertensive patients randomized to an ACE inhibitor as first-line therapy vs those randomized to either a calcium antagonist (amlodipine), or an alpha-adrenergic blocker (doxazosin) or a thiazide-like diuretic (chlorthalidone) as first-line therapy will be lower in individuals with the AA genotype of angiotensinogen-6 compared to the analogous relative risk in carriers of the G allele. The primary response variable in ALLHAT is time from randomization to development of CHD. In GenHAT, the test for interaction will be employed within the framework of Cox regression employing treatment and genotype as main effects. Ratios of hazard ratios in a 2 Â 2 Â 2 design based on the work of Peterson and George 14 were used to evaluate effect sizes given the fixed sample size provided by ALLHAT and the blood samples obtained. For quantitative traits, an example of a GenHAT hypothesis is that the change in the trait (eg blood pressure) for hypertensive patients randomized to an ACE inhibitor as first-line therapy vs hypertensive patients randomized to one of the other drugs as first-line therapy is lower in patients with the AA genotype of angiotensinogen-6 compared to the analogous change carriers of the G allele. The formal test for interaction between treatment and genotype with regard to quantitative traits will be undertaken using a linear regression model with treatment and genotype as main effects. Since the sample size in ALLHAT is fixed, we used estimated event rates within each treatment group, the number assigned to each treatment group, and estimated genotype frequencies within the ALLHAT cohort to estimate the power to detect interactions. Power calculations were based on one primary question for each of the six initial candidate genes (see Table 3 ). The sample sizes within each treatment group are: chlorthalidone, 15 255; lisinopril, 9 054; amlodipine, 9 048; and doxazosin, 9 061. Using the estimates of a 6-yr CHD incidence rate of 0.0686 for the chlorthalidone group and 0.0580 for either of the lisinopril, amlodipine, or doxaszozin groups, we estimated the number of events for each trial arm. (The rationale for the ALLHAT incidence rates is provided in the Appendix of the ALLHAT design paper, 6 the ALLHAT protocol, and an update due to the reduction in the sample size of the lipid-lowering trial from 20 000 to 10 000). These estimates took into account treatment group crossovers and competing risk. Using the expected frequencies of the genotypes (accounting for the known race distribution within ALLHAT where possible) for the six genes, the estimated CHD rates for the treatment groups, and a test for interaction referenced above, 14 we have 80% power to detect a ratio of hazard ratios of 0.0.65-0.72 for the six hypotheses (see Table 3 ). Several assumptions were made in these calculations. First, we do not have genotypes on all participants. About 5% of participants are missing either DNA or the DNA fails to amplify. About 6% of ALLHAT participants are missing baseline labs, but about half of them have had subsequent blood samples. An error rate of 3% in genotyping and 5% in phenotyping diminishes the detectable hazard ratios by 0.01, ie, from 0.68-0.67. Estimates of power for blood pressure change from baseline show that the power to detect gene-drug interactions for a 2-3 mmHg change is close to 100%.
As with any large study, once the primary hypotheses have been addressed, there will be no adjustment for multiple comparisons. 15 All secondary questions need to be considered as exploratory since the study was not powered to address them and will have to be replicated by others to provide convincing evidence as to their authenticity. Many studies, such as Framingham, Nurses Health Study, HDFP and MRFIT, to name a few, addressed many questions, eg, multiple endpoints and multiple subgroups, without adjustment for multiple comparisons.
RESULTS
Overall, 59.6% of the ALLHAT participants are white (n ¼ 25 292) and 35.6% are black (n ¼ 15,094). There are 8100 Hispanic participants, and about two-thirds designate themselves as 'white Hispanics'. About 52% of the participants are men, and the mean age is 66.9 7 7.7 years. About 36% report diabetes mellitus and just over 25% percent report CHD. 16 The overall mean body mass index is 29.8 kg m À2 , indicating a high prevalence of obesity. Table  5 presents the baseline characteristics of the study participants by randomized treatment group. A detailed summary of the baseline characteristics of ALLHAT participants is available. 17 As defined by the randomization scheme, the chlorthalidone group is the largest, and the other three treatment arms have in excess of 9000 participants. There are two very small, but statistically significant differences between the amlodipine and chlorthalidone groups: those randomized to amlodipine were less likely to have a history of CHD and had lower values for serum creatinine.
As of March 2002, about 22 000 DNA samples (50% of the anticipated total) are completely processed and genotyped for several variants. The missing genotype information ranges from 0.7%-6.1% across the variants typed and the majority of the missing data is due to failure of the DNA to amplify. Tests for Hardy-Weinberg equilibrium indicate all of the variants are in equilibrium (data not presented).
DISCUSSION
The GenHAT study represents an enormous opportunity to test whether hypertensive genetic variants interact with a number of different antihypertensive treatments to modify the risk of fatal and non-fatal cardiovascular outcomes. ALLHAT is the largest, randomized, double-blind trial ever conducted in hypertension, including more than 42 000 patients. The gender and ethnic diversity of the study population provides an opportunity to determine if the associations between genetic variation and treatment are comparable across subgroups of the population. In addition, this enriched CHD patient population allows GenHAT to test a number of important hypotheses relating the hypertensive variants and treatment to atherosclerotic heart disease, blood pressure and left ventricular hypertrophy, to name a few, both at baseline and during follow-up.
ALLHAT randomized participants to one of four treatments. In addition to the statistical utility of randomization, the allocation to one of four different drugs provides a better characterization of the genetic architecture of gene and treatment interactions in hypertension. For example, the AGT-6 GG genotype, which is associated with an increased expression of angiotensinogen, 18 may be more responsive to an ACE inhibitor than to agents that do not target the reninangiotensin system. However, the AGT-6 GG genotype may also respond well to diuretics, since sodium loss in the kidney upregulates renin, which subsequently upregulates angiotensinogen. Trials in which participants are randomized to only one agent would not have the ability to characterize complex associations between multiple treatments for a given treatment.
The multitude of risk factors and the minimum age inclusion criteria of 55 yrs support the likelihood that GenHAT will have the anticipated number of fatal CHD and non-fatal MI events to accomplish its aims. The mean age of the ALLHAT participants is 67 yrs, about 22% are current smokers, 36% are diabetic and 22% have prevalent CHD. The large number of anticipated events will also provide an opportunity to assess gene-treatment interactions within important subgroups, such as diabetics and the elderly. For example, McNamara et al 19 recently reported that among 328 elderly individuals with impaired systolic function, the ACE DD genotype conferred a poor prognosis in patients not treated with beta-blocking agents, but was unrelated to survival in the treated patients. GenHAT will be able to test such hypotheses with a much larger sample size, thereby detecting important interactions with potentially weaker effects.
Strengths and limitations
The number of statistical tests planned impact the study's power since the sample size is fixed. We calculated the power for the primary hypothesis test using an alpha level of 0.05. If we split the primary hypothesis by the six genotypes chosen a priori, the alpha level required to detect a significant association would decrease to 0.0083, and the ratio of hazard ratios detectable would be 0.65-0.68 instead of 0.7-0.74. All other hypotheses will be considered exploratory and will require confirmation in other studies. Despite the issue of multiple testing, which is not unique to the GenHAT study, there are a number of strengths: the ethnic and gender diversity of the sample, the randomized, double-blind design and the large sample size. In summary, the use of pharmacogenetics to characterize response to antihypertensive therapy may open new avenues for more effective and specific control of blood pressure and its related complications. The Genetics of Hypertension Associated Treatment Study, GenHAT, the largest pharmacogenetics study ever conducted, provides a unique opportunity to further understanding of the genetic basis to treatment response for important cardiovascular endpoints in unique populations at high risk of cardiovascular disease.
